Anavex Life Sciences Corp. (NASDAQ:AVXL) shares traded down 6% during mid-day trading on Monday . The company traded as low as $3.60 and last traded at $3.61, with a volume of 860,322 shares. The stock had previously closed at $3.84.

A number of research analysts have issued reports on the stock. Zacks Investment Research raised shares of Anavex Life Sciences Corp. from a “hold” rating to a “buy” rating and set a $5.00 price target for the company in a report on Tuesday, May 31st. Maxim Group reissued a “buy” rating and set a $15.00 target price on shares of Anavex Life Sciences Corp. in a report on Wednesday, May 11th. Finally, FBR & Co reissued a “buy” rating on shares of Anavex Life Sciences Corp. in a report on Wednesday, June 22nd.

The firm’s market capitalization is $128.91 million. The stock has a 50-day moving average of $5.67 and a 200 day moving average of $4.87.

Anavex Life Sciences Corp. (NASDAQ:AVXL) last announced its quarterly earnings data on Wednesday, May 11th. The company reported ($0.06) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.10. Equities analysts forecast that Anavex Life Sciences Corp. will post ($0.34) EPS for the current year.

Anavex Life Sciences Corp., is a clinical-stage biopharmaceutical company engaged in the development of drug candidates. The Company’s lead compounds include ANAVEX 2-73, ANAVEX PLUS, a combination of ANAVEX 2-73 with donepezil (Aricept), ANAVEX 19-144, ANAVEX 1-41, ANAVEX 7-1037, ANAVEX 3-71, ANAVEX 1079, ANAVEX 1519 and ANAVEX 1066 being developed to treat Alzheimer’s disease and other central nervous system (CNS) diseases.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.